Glaxo to buy antibody firm Domantis for 230 mln stg

LONDON, Dec 8 (Reuters) GlaxoSmithKline Plc has agreed to buy privately owned biotech company Domantis Ltd, a specialist in developing a new generation of antibody drugs, for 230 million pounds (2.8 million).

Europe's biggest drugmaker said Domantis would become part of its biopharmaceuticals drug discovery unit while continuing to operate from laboratories in Cambridge, England.

The deal is the latest in a string of recent biotech acquisitions by large pharmaceutical companies eager to boost their pipelines of new medicines.

REUTERS SBA RS1921